Deals In Depth: April 2014
Celgene penned two major collaborations; Zimmer and Biomet created an orthopedics device giant in their $13.4B merger. Biopharma financing totaled $2.7B in April; and device funding reached $354M, with two IPOs representing 38% of the total.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.